As part of the seminar, Angus Russell, Chief Executive of Shire plc, will comment on the company’s longer term strategic aim to become the leading specialty biopharmaceutical company focusing on meeting the needs of the specialist physician. Commenting on Shire HGT, Angus Russell said; “The seminar represents a real opportunity to demonstrate the depth and the potential of our HGT business and I am excited about its prospects in the short, medium and long term. We aim to combine the talent within Shire with the wide range of opportunities that exist within our industry to deliver exceptional shareholder value and to improve the daily quality of life for people with symptomatic diseases. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. read more

Technorati Tags: , provided, shire, business, company, data, investor seminar news